在不同临床条件下可变的泰莫西林蛋白结合和药理动力学:对目标实现的影响
Letao Li1, Perrin Ngougni Pokem2, Sebastiaan D T Sassen1,3,4
1Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands.
British journal of clinical pharmacology
|January 22, 2025
概括
由于复杂的蛋白质结合,需要调整泰莫西林的剂量. 持续输液比间歇输液更有效地达到药物标水平,特别是在败血症患者中.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 临床药房 临床药房
背景情况:
- 泰莫西林是一种用于扩展谱β-乳糖酶 (ESBL) 感染的抗生素.
- 它的蛋白质结合是复杂的,影响药物的疗效.
- 优化泰莫西林剂量对于治疗耐药细菌菌株至关重要.
研究的目的:
- 预测不同患者群体中未结合的泰莫西林度.
- 评估这些度对目标实现概率 (PTA) 的影响.
- 改进泰莫西林的剂量建议,以改善患者的治疗结果.
主要方法:
- 使用非线性混合效应建模来分析血药理动力学.
- 包括来自健康志愿者和患有尿路感染,腹腔炎和败血症-ICU的患者的数据.
- 模拟对不同剂量方案和患者组的PTA进行了比较.
主要成果:
- 一个两部分蛋白质结合模型准确地描述了泰莫西林度.
- 泰莫西林清除受肌素清除,专蛋白和C反应蛋白的影响.
- 与跨组间歇性输液相比,连续输液显示出优越的PTA.
结论:
- 在患者群体之间存在着西林清除和未结合分量的显著变异.
- 标准的2g q12h剂量可能不足.
- 持续输液是一种更有效的策略,可以实现最佳的目标,特别是在高功能和低炎症的患者中.
相关概念视频
Factors Affecting Protein-Drug Binding: Drug-Related Factors
75
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
75
Factors Affecting Protein-Drug Binding: Patient-Related Factors
34
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
34
Factors Affecting Protein-Drug Binding: Protein-Related Factors
116
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
116
Protein-Drug Binding: Mechanism and Kinetics
271
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
271
Physiological Pharmacokinetic Models: Assumption with Protein Binding
30
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
30
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
114
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
114


